Neufang Achim, Zhghenti Valerian, Vargas-Gomez Carolina, Umscheid Thomas, von Flotow Peter, Schmiedel Rainer, Savvidis Savvas
Department of Cardiac and Vascular Surgery, University Medical Center, Johannes Gutenberg-University, 55131 Mainz, Germany.
Department of Vascular Medicine, Helios Dr. Horst Schmidt Hospital (Teaching Hospital of Johannes Gutenberg-University, Mainz), 65199 Wiesbaden, Germany.
J Clin Med. 2023 Apr 16;12(8):2895. doi: 10.3390/jcm12082895.
Autologous vein bypass provides excellent long-term results in critical limb-threatening ischemia (CLTI), but a substantial portion of patients have insufficient vein length. In limbs with two distal outflow vessels and limited vein length, a vascular prosthesis may be combined with autologous vein for a sequential composite bridge bypass (SCBB). Results regarding graft function, limb salvage and reinterventions are presented.
Between January 2010 and December 2019, 47 consecutive SCBB operations with a heparin-bonded PTFE-prosthesis and autologous vein were performed. Grafts were followed with a duplex scan with prospective documentation in a computerized vascular database. Retrospective analysis of graft patency, limb salvage and patient survival was performed.
Mean follow-up was 34 months (range 1-127 months). 30-day mortality was 10.6% and 5-year patient survival 32%. Postoperative bypass occlusion occurred in 6.4% and late occlusions or graft stenoses in 30%. Two prostheses developed late infection and seven legs were amputated. Primary, primary assisted, secondary patency and limb salvage rate were 54%, 63%, 66% and 85% after 5 years, respectively.
SCBB patency and limb salvage were good despite a high early postoperative mortality. Combination of a heparin-bonded PTFE-prosthesis and autologous vein appears to be a valuable tool in CLTI in case of insufficient vein.
自体静脉搭桥术在治疗严重肢体缺血(CLTI)方面能取得优异的长期效果,但相当一部分患者的静脉长度不足。在有两条远端流出血管且静脉长度有限的肢体中,可将血管假体与自体静脉联合用于序贯复合桥接搭桥术(SCBB)。本文介绍了关于移植物功能、肢体挽救及再次干预的结果。
2010年1月至2019年12月期间,连续进行了47例使用肝素结合聚四氟乙烯(PTFE)假体和自体静脉的SCBB手术。通过双功超声扫描对移植物进行随访,并将相关资料前瞻性记录于计算机血管数据库中。对移植物通畅情况、肢体挽救情况及患者生存率进行回顾性分析。
平均随访时间为34个月(范围1 - 127个月)。30天死亡率为10.6%,5年患者生存率为32%。术后旁路闭塞发生率为6.4%,晚期闭塞或移植物狭窄发生率为30%。两个假体发生晚期感染,7条腿被截肢。5年后的一期通畅率、一期辅助通畅率、二期通畅率及肢体挽救率分别为54%、63%、66%和85%。
尽管术后早期死亡率较高,但SCBB的通畅率和肢体挽救情况良好。在静脉不足的情况下,肝素结合PTFE假体与自体静脉联合应用似乎是治疗CLTI的一种有价值的方法。